Dr. George J. Alangaden, MD

Dr. Alangaden practices at Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health.

Dr. Alangaden's NPI, 1194762799, was assigned on June 1, 2006. Dr. Alangaden holds FM license 4301055076.

Dr. Alangaden's primary practice is Henry Ford Hospital, at 2799 W Grand Blvd, Detroit, MI 48202 in Wayne County. The practice phone is (313) 916-2600.

Dr. Alangaden's primary practice is Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health. Dr. Alangaden is also affiliated with Henry Ford Macomb Hospital. The medical group on file is Henry Ford Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alangaden practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Alangaden's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Alangaden is licensed in FM.

CMS data shows 339 Medicare services from Dr. Alangaden across 6 procedure codes in 2024, for 175 Medicare patients. Medicare paid $34,807 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 175 Medicare patients who saw Dr. Alangaden in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 42% are also on Medicaid. Their average risk score is 4.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alangaden's median patient age at 66, with 38% women.

In 2024, Dr. Alangaden wrote 414 Medicare Part D claims for 80 patients. 23% of them were for generic drugs. CMS names the drug for 324 of them, across 14 drugs with 11 or more claims each, at $902,149 in total drug cost. In 2023, CMS named 319 claims across 13 drugs.

Dr. Alangaden accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alangaden as offering telehealth.

Dmand AI links 73 papers to Dr. Alangaden, published from 2007 to 2025. 2022 was the busiest year, with 7. The most frequent topics are Anti-Bacterial Agents, Cross Infection and Intensive Care Units. Dr. Alangaden has published most often in Infect Control Hosp Epidemiol. Dr. Alangaden's most frequent co-authors are Mayur S. Ramesh, MD, Geehan Suleyman, MD and Marcus John Zervos, MD.

Dmand AI links Dr. Alangaden to 4 clinical trials. Conditions studied include Bacteremia and Sepsis. Shire sponsors the most, 2.

CMS Open Payments shows 31 general payments to Dr. Alangaden from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. Astellas Pharma Global Development paid the most, $4,631. It also lists 1 research payment totaling $1,392 in 2017.